Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis

Transpl Infect Dis. 2011 Jun;13(3):244-9. doi: 10.1111/j.1399-3062.2011.00624.x. Epub 2011 Mar 17.

Abstract

Background: Cytomegalovirus (CMV) disease occurs frequently after cessation of antiviral prophylaxis in CMV-seronegative kidney transplant recipients from seropositive donors (D+R-), and the risk factors are incompletely defined.

Method: We retrospectively assessed the incidence, clinical features, and risk factors for CMV disease in a cohort of D+R- kidney transplant recipients who received antiviral prophylaxis at a single US transplant center using descriptive statistics and Cox proportional hazards models.

Results: CMV disease developed in 29 of 113 (26%) D+R- patients at a median of 185 days (interquartile range 116-231 days) post transplant, including CMV syndrome (66%) and tissue invasive disease (34%). The incidence of CMV disease was higher in patients who underwent re-transplantation (57% vs. 24%) and this factor was independently associated with a higher risk of CMV disease in multivariable analysis (hazard ratio, 4.02; 95% confidence interval, 1.3-13; P = 0.016). Other demographic and transplant variables were not independently associated with a risk of late-onset CMV disease.

Conclusions: Despite a comprehensive analysis of patient and transplant variables, only re-transplantation was identified as a risk factor for CMV disease in D+R- kidney transplant recipients who received antiviral prophylaxis, but had limited clinical predictive value. The development of novel laboratory markers to identify patients at greatest risk for CMV disease should be a priority for future studies.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antibodies, Viral / blood*
  • Antiviral Agents / therapeutic use*
  • Chemoprevention
  • Cytomegalovirus / immunology
  • Cytomegalovirus Infections / diagnosis
  • Cytomegalovirus Infections / epidemiology*
  • Cytomegalovirus Infections / prevention & control
  • Cytomegalovirus Infections / virology
  • Female
  • Ganciclovir / therapeutic use*
  • Humans
  • Incidence
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Proportional Hazards Models
  • Risk Factors
  • Time Factors
  • Tissue Donors*

Substances

  • Antibodies, Viral
  • Antiviral Agents
  • Ganciclovir